Med. praxi. 2018;15(4):194-196 | DOI: 10.36290/med.2018.037
Chronic hepatitis C therapy using Directly Acting Antivirals (DAA) has high efficacy (till 100 %), minimum contra-indications andextraordinarily favorable safety profile. Primarily, it is necessary to pay attention to drug-drug interactions. However they arewell documented and successfully resolvable already in general clinical practice. Current possibilities of interferon-free therapyrepresent combinations of sofosbuvir with other DAA (velpatasvir, velpatasvir + voxilaprevir, ledipasvir), combination of paritaprevirboosted by ritonavir + ombitasvir ± dasabuvir, and fixed combinaton of elbasvir and grazoprevir. Fixed combinations ofglecaprevir + pibrentasvir will be available in the Czech Republic during the year 2018.
Published: September 1, 2018 Show citation